No Data
No Data
B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Hold Rating
LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)
Repare Therapeutics Names Forte as President, CEO
Express News | Repare Therapeutics- Exploring Strategic Alternatives and Partnerships Across Portfolio, Including for Lunresertib & Camonsertib
Express News | Repare Therapeutics: Lloyd M. Segal Resigned as President, CEO and Director